The Multilateral Evaluation Mechanism (MEM) is a peer review process that measures the progress of the actions taken by OAS member states to address the drug problem and related crimes. The MEM is the instrument approved to measure the implementation of the current OAS Hemispheric Strategy on Drugs and its Plan of Action, guaranteeing its alignment to the commitments acquired in the Special Session of the United Nations General Assembly of 2016 (UNGASS 2016) and in the general framework of the United Nations 2030 Agenda on Sustainable Development. MEM evaluations are carried out through drug control progress reports, highlighting both the strengths and weaknesses of the OAS member states, which are drafted by governmental experts designated by each country, which are part of a multidisciplinary group that guarantees objectivity and the multilateral component of the MEM.

Objectives
  • Achieve full application of the Hemispheric Drug Strategy 2020 and its Plan of Action 2021-2025 in OAS member states’ policies and, consequently, an alignment with the commitments acquired in the Special Session of the United Nations General Assembly of 2016 (UNGASS 2016) and within the general framework of the United Nations 2030 Agenda on Sustainable Development.
  • Strengthen mutual trust, dialogue, and hemispheric cooperation to confront, with greater efficiency and efficacy, the diverse aspects of the world drug problem.
  • Follow-up on the individual and collective progress of hemispheric efforts of all countries participating in the Mechanism, indicating both the results attained as well as the obstacles faced by the countries.
  • Promote, within the CICAD framework, the following actions based on the evaluation results:
    • Support OAS member states in the planning and execution of their national drug plans;
    • Contribute to the strengthening of member states' capacity to confront the drug problem; and
    • Stimulate the development of technical assistance and training programs and the exchange of experiences and best practices according to each country’s needs. 
  • Produce and periodically publish national evaluation reports and hemispheric briefs that provide reliable information on the drug policy situation in the countries for each of the thematic areas in the current Hemispheric Plan of Action on Drugs.
  • Strengthen multilateral participation to ensure an objective evaluation of the member states' efforts to address the drug problem.
  • Encourage, through CICAD, the strengthening of cooperation and coordination with other regions, the United Nations, and other international entities.
Activities

The Multilateral Evaluation Mechanism (MEM) is an instrument for measuring anti-drug activities carried out by the member states of the Inter-American Drug Abuse Control Commission (CICAD, by its Spanish language acronym). This measurement is carried out through the preparation of reports evaluating the progress of drug control.


The reports produced within the MEM process are written by government experts appointed by the OAS member states. Each country is entitled to one main expert and alternate experts, with the exception that each country has only one voice and that the experts do not participate in the evaluation of their own country. In this way, the Governmental Expert Group (GEG) is composed of a multidisciplinary group that guarantees objectivity and the multilateral component of the MEM.


Since its establishment in 1998, the MEM has contributed to the OAS member states' improvements of a wide array of national drug polices and strategies. These include:


  • Ratifying international conventions and bilateral agreements.
  • Conducting studies/surveys on drug use, at a national, university, and school level.
  • Implementing and strengthening of demand reduction programs.
  • Enactment of laws and control regulations on chemical substances and pharmaceutical products.
  • Establishing intelligence information exchange mechanisms for the control of drug trafficking.


In its eighth round, the MEM operational process was reviewed to carry out annual thematic evaluations, in accordance with the Hemispheric Plan of Action 2021-2025, during its first three years of execution, concluding with a comprehensive evaluation in its final year. Moreover, at the end of each thematic evaluation, a hemispheric brief will be prepared on regional trends derived from the national reports. 


More Results
Results
7 Comprehensive Multilateral Evaluation Mechanism rounds completed
474 Multilateral Evaluation Mechanism national reports published
7 Multilateral Evaluation Mechanism hemispheric reports published
33 Multilateral Evaluation Mechanism thematic evaluations on drug demand reduction completed in December 2021
1 Multilateral Evaluation Mechanism hemispheric brief on drug demand reduction published in March 2022
1 Multilateral Evaluation Mechanism hemispheric brief on drug supply reduction published in March 2023
32 Multilateral Evaluation Mechanism thematic evaluations on drug supply reduction completed in December 2022
More Publications
Publications
March, 2024
Hemispheric Brief 2024
8th Round
Team
Luis Adrián Noble
Unit Chief
Martín Cubas
Specialist
Karen Sanjines
Specialist
Dayana Rios
Specialist
Strategic Partners
Evaluation Reports
Back

Evaluation Reports by Rounds

Eighth Evaluation Round - Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation
Documents
Hemispheric Brief 2024 (published in March 2024)

Antigua and Barbuda Antigua and Barbuda
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Argentina Argentina
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Barbados Barbados
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Belize Belize
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Bolivia Bolivia
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Brazil Brazil
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Canada Canada
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Chile Chile
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Colombia Colombia
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Costa Rica Costa Rica
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Dominica Dominica
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Dominican Republic Dominican Republic
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Ecuador Ecuador
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
El Salvador El Salvador
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Grenada Grenada
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Guatemala Guatemala
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Guyana Guyana
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Haiti Haiti
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Honduras Honduras
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Jamaica Jamaica
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Mexico Mexico
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Panama Panama
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Paraguay Paraguay
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Peru Peru
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Saint Kitts and Nevis Saint Kitts and Nevis
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Saint Lucia Saint Lucia
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Saint Vincent and the Grenadines Saint Vincent and the Grenadines
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Suriname Suriname
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
The Bahamas The Bahamas
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Trinidad and Tobago Trinidad and Tobago
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
United States of America United States of America
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)
Uruguay Uruguay
Evaluation Report on Drug Policies: Institutional Strengthening; Research, Information, Monitoring, and Evaluation; and International Cooperation (published in December 2023)